Clinical Trial Update: A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A [Phase 4]

View source ↗

Summary

A Phase 4 post-approval study by Bayer evaluating safety and effectiveness of Kovaltry (octocog alfa) in Chinese children, adolescents, and adults with severe H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Kovaltry (octocog alfa)

Snippet

Sponsor: Bayer | Conditions: Hemophilia A | Phase 4 | Status: COMPLETED | Results posted: 2025-04-18